Indoor Tanning Legislation 2018
…Source: AIM at Melanoma and StateNet. Note: List may not be comprehensive but is representative of the state laws that…
Indoor Tanning Legislation 2018
…Source: AIM at Melanoma and StateNet. Note: List may not be comprehensive but is representative of the state laws that…
Indoor Tanning Legislation 2017
…for 12 months. Source: AIM at Melanoma and StateNet. Note: List may not be comprehensive but is representative of the state…
Indoor Tanning Legislation 2016
…for 12 months. Source: AIM at Melanoma and StateNet. Note: List may not be comprehensive but is representative of the state…
Indoor Tanning Legislation 2015
…for 12 months. Source: AIM at Melanoma and StateNet. Note: List may not be comprehensive but is representative of the state…
Indoor Tanning Legislation 2014
…for 12 months. Source: AIM at Melanoma and StateNet. Note: List may not be comprehensive but is representative of the state…
Share your Gratitude
…prefer not to respond Stage of Melanoma Stage IStage IIStage IIIStage IVN/APrefer not to respond What are you Grateful For?*…
Indoor Tanning Legislation 2021
…Source: AIM at Melanoma and StateNet. Note: List may not be comprehensive but is representative of the state laws that…
Costs of Participating in Clinical Trials
…Routine care for melanoma would be needed regardless of whether someone is in a clinical trial or not. For example, visits to…
Alkermes’s disappointment hones melanoma niche focus
…melanoma patients. Alkermes is therefore focusing its efforts primarily on mucosal melanoma, where the group sees a fast path to…
,
,
Early Clinical Trial Shows Drug Activity to Work in Patients with Acral and Mucosal Melanoma
Results of a Phase 1/2 clinical trial showed promising data for patients with advanced acral and mucosal melanoma. The results…
,
Recent Posts
Jun. 09, 2026
The FDA Just Approved a New Sunscreen Ingredient— What It Means for Patients with Skin Cancer, Survivors, and the General Public
Jun. 05, 2026
Fifth Annual Evening in Memory of Valerie Guild
Jun. 05, 2026
Results for darovasertib in combination with crizotinib in first line HLA*A2:01-negative metastatic uveal melanoma met the study’s primary objective
Jun. 05, 2026
Encouraging results with anzutresgene autoleucel in patients with uveal melanoma and other melanoma subtypes
Jun. 05, 2026